ePT--the Electronic Newsletter of Pharmaceutical Technology, Mar 10, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Mar 10, 2011
News
Japan Halts Use of Pfizer and sanofi Vaccines
By Stephanie Sutton
Japan has suspended the use of two pediatric vaccines made by Pfizer and sanofi following the deaths of four children in three days.
Regulatory Roundup: FDA Posts PDUFA Meeting Minutes
FDA Posts PDUFA Meeting Minutes
Hamburg Describes Efforts to Develop Medical Countermeasures
By Erik Greb
At a conference on preserving national security at the University of Pittsburgh Medical Center last week, FDA Commissioner Margaret Hamburg stressed the importance of medical countermeasures for responding to natural and deliberate threats to public health.
AstraZeneca Discontinues Pulmicort Production
By Patricia Van Arnum
AstraZeneca announced this week that it will discontinue the production of Pulmicort (budesonide) 100 and 200 µg/dose HFA (hydrofluoroalkane) pressurized metered-dose inhaler (pMDI) due to manufacturing issues related to technical aspects of the device, which prevents the ongoing manufacture of the product.
Week of Mar. 7, 2011: Company and People Notes: WuXi and BMS Form Collaboration; F. Michael Ball Leaves Allergan for Hospira; and More.
WuXi and BMS Form Collaboration; F. Michael Ball Leaves Allergan for Hospira; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here